EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders

计划入组 18 人 · 首次发布于 2026 年 3 月 4 日

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis

计划入组 80 人 · 首次发布于 2026 年 3 月 23 日

Bortezomib Plus Rituximab for EBV+ PTLD

计划入组 7 人 · 首次发布于 2010 年 1 月 28 日

Rituximab(MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo, Ituxredi)

Rx

EBV-TCR-T cells (allogenic, EBV-associated hemophagocytic lymphohistiocytosis/EBV infection)

Tabelecleucel(Ebvallo)

Associated Capital

United States

Associated Medical Supplies Ltd

Canada

Rare Disease Research, LLC

Atara Biotherapeutics Submits BLA for Tabelecleucel to Treat EBV+ PTLD

FDA Grants Priority Review to Tabelecleucel for EBV+ PTLD Treatment

Cell Therapy Shows Promise for EBV-Driven Post-Transplant Lymphoproliferative Disease